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Abstract  Atypical  pneumonias,  a  group  of  diseases  relatively  unfamiliar  to  most  clinicians,
are caused  by  bacteria  not  normally  associated  with  pneumonia  and  usually  occur  in  patients
with some  kind  of  comorbidity.  They  can  present  as  extrapulmonary  infections,  and  progno-
sis can  differ  from  typical  pneumonias.  Many  clinicians  are  unfamiliar  with  the  diagnosis  of
these diseases,  and  they  are  often  incorrectly  treated.  In  this  review,  we  describe  the  clinical
manifestations  of  the  most  common  forms  of  atypical  pneumonia,  and  outline  the  diagnostic
procedures  and  therapies  used  in  each  case.  In  this  way,  hope  to  give  physicians  and  other
healthcare professionals  the  knowledge  and  diagnostic  tools  they  need  to  deal  with  cases  in
which atypical  pneumonia  is  suspected.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Published  by  Masson  Doyma  México
S.A. All  rights  reserved.
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Resumen  Las  neumonías  atípicas,  un  grupo  de  patologías  relativamente  desconocidas  por  los
médicos, son  causadas  por  microorganismos  que  no  se  consideran  tradicionales.  Este  tipo  de
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Diagnóstico
pueden  presentar  infecciones  extrapulmonares  y  pronósticos  distintos  a  los  de  las  neumonías
típicas. El  diagnóstico  de  estas  patologías  no  es  muy  conocido,  por  lo  que  el  tratamiento  no
siempre es  el  adecuado.  En  este  trabajo  de  revisión,  mencionamos  las  manifestaciones  clínicas
causadas por  los  principales  microorganismos  que  causan  neumonías  atípicas,  así  como  las  car-
acterísticas  particulares  de  los  métodos  diagnósticos  disponibles  y  los  respectivos  tratamientos
de las  neumonías,  en  búsqueda  de  que  los  médicos  y  profesionales  de  la  salud  se  familiaricen  y
obtengan un  mayor  conocimiento  sobre  este  tema  a  la  hora  de  enfrentarse  a  un  caso  sospechoso
de una  neumonía  atípica.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Publicado  por  Masson  Doyma  México
S.A. Todos  los  derechos  reservados.
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The  term  atypical  or  walking  pneumonia  was  ﬁrst  coined  in
1938  to  refer  to  a  group  of  pneumonias  caused  by  bacteria
or  other  pathogens  not  usually  associated  with  pneumo-
nia.  The  symptomology  and  radiographic  images  of  walking
pneumonias  differ  from  conventional  pneumonia,  and  they
occasionally  present  with  extrapulmonary  infection.1,2
The  5  most  common  pathogens  that  cause  atypical
pneumonia  are:  Legionella  pneumophila, Chlamydophila
pneumoniae,  Mycoplasma  pneumoniae, Coxiella  Burnetti
and  Chlamydophila  psitacci.3 Infection  is  most  commonly
associated  with  children  in  day  care  centres,  elderly  indi-
viduals,  smokers,  and  patients  with  chronic  diseases  or
immunodeﬁciency  disorders.4
All  physicians  must  be  aware  of  these  risk  factors  and
of  the  clinical  and  radiological  characteristics  of  atypical
pneumonias.  The  following  overview  of  these  diseases  and
their  3  main  causative  pathogens  will  enable  physicians  to
recognize  the  early  signs  of  such  infections  and  choose  the
most  effective  treatment.5
Legionella pneumophila
Morphological  and  structural  characteristics
Legionella  pneumophila  is  an  aerobic,  Gram-negative,
nonencapsulated,  non-spore-forming,  ﬂagellated,  intracel-
lular  bacterium,  often  characterized  as  being  a  coccobacil-
lus.  Its  cell  wall  contains  fatty  acid  with  high  ubiquinone
content  and  the  capacity  to  form  bioﬁlms.  It  is  oxidase,
catalase  and  gelatinase-positive,  has  no  nitrate-reducing
capacity,  and  it  can  be  observed  with  fascin  staining.
L.  pneumophila  is  an  insidious  bacterium  that  requires
cysteine  and  iron  to  thrive.  For  this  reason,  it  is  detected
by  culture  on  buffered  charcoal  yeast  extract  (BCYE),
polymyxin  B,  anisomycin  and  cefamandole  agar.  It  can  also
be  isolated  by  amoebal  coculture.1--3There  are  over  50  species  of  Legionella, but  evidence
has  shown  that  only  19  of  these  cause  infection  in  humans.
There  are  also  64  subgroups  of  the  Legionella  genus,  and  15
L.  pneumophila  serogroups.1,3
i
a
hpidemiology
.  pneumophila  infection  is  uncommon,  and  usually  occurs
n  immunocompromised  individuals.  Over  90%  of  infections
n  humans  are  caused  by  L.  pneumophila  serogroup  1.
The  bacterium  is  ubiquitous,  and  is  commonly  found
n  fresh  water,  rivers,  lakes,  and  in  muddy,  damp  soil.  It
an  also  thrive  in  air  conditioning,  water  heating,  ventila-
ion  and  shower  systems.  L.  pneumophila  can  survive  for
rolonged  periods  under  most  climatic  conditions.  It  can
ithstand  temperatures  ranging  from  0  to  68 ◦C,  and  is  chlo-
ine  resistant.5
Epidemiological  reports  on  the  incidence  of  disease
aused  by  this  pathogen  in  Mexico  and  the  rest  of  the  world
re  somewhat  out-dated.  No  outbreaks  of  Legionnaires’  dis-
ase  have  so  far  been  reported  in  Mexico.6,9
Legionella  causes  between  2%  and  9%  of  all  cases
f  community-acquired  pneumonia,  and  between  1%  and
0%  of  nosocomial  pneumonia11.  Most  epidemics  occur  in
he  summer  and  autumn.  Approximately  20,000  cases  of
egionnaires’  disease  are  reported  annually  in  the  United
tates.  Infection  usually  occurs  in  middle-aged  or  elderly
ndividuals,  particularly  those  with  cardiac  or  pulmonary
omplications.  It  also  targets  smokers,  and  immunocompro-
ised  individuals.1,7
isk  factors
here  is  no  evidence  for  person-to-person  transmission  of
egionnaires’  disease.  The  bacteria  are  transmitted  via  con-
aminated  aerosols  generated  by  nebulisers  and  humidiﬁers.
hey  can  also  be  transmitted  directly  during  surgical  inter-
entions,  and  by  drinking  contaminated  water.7
Immunocompromised  individuals,  solid  organ  transplant
ecipients,  patients  recovering  from  surgery  or  receiving
ndotracheal  ventilation,  patients  admitted  to  critical  care
nits,  or  individuals  exposed  to  ventilation  systems  are  most
t  risk  for  infection.  Some  studies  have  mentioned  naso-
astric  intubation  to  be  associated  with  risk  for  Legionella
nfection.
Other  risk  factors  include  contact  with  stagnant  water,
ir  conditioning  systems,  rivers,  lakes,  and  domestic  water
eating  systems.8
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linical  manifestations
erology  testing  has  shown  that  infection  is  often  asymp-
omatic.  Symptomatic  L.  pneumophila  infection  can  present
ither  as  severe  pneumonia,  called  Legionnaire’s  disease,  or
s  a  ﬂu-like  condition  known  as  Pontiac  fever.9
Legionnaire’s  disease  is  characterized  by  clinical  and
adiological  signs  consistent  with  pneumonia.  Initial  symp-
oms  include  anorexia,  vomiting,  myalgia  and  headache.
ver  90%  of  patients  present  fever  between  12  and  24  h
fter  onset  of  the  ﬁrst  symptoms.  Fever  is  high  grade,  usu-
lly  over  39.4 ◦C,  and  is  accompanied  by  shivering  and  cough
roducing  little  or  no  sputum.  Most  patients  complain  of
yspnoea,  and  in  60%  the  mental  state  is  altered,  with
ymptoms  ranging  from  lethargy  to  obtundation.  Chest  pain
s  common  in  immunocompromised  patients,  and  can  be
onfused  with  pulmonary  thromboembolism.  These  patients
an  also  present  fever  alone,  with  no  other  symptoms
f  pneumonia,  despite  radiological  evidence  of  pulmonary
nﬁltrates.  Around  50%  of  patients  present  gastrointestinal
ymptoms,  such  as  diarrhoea  with  blood  and  mucous,  and
ntestinal  colic.  Other  manifestations  include  hypotension,
radycardia,  bronchospasm,  toxic  encephalopathy  and  rash.
adiological  signs  are  similar  to  those  of  pneumonia  caused
y  other  pathogens.9,10,12
In  Pontiac  fever,  patients  present  ﬂu-like  symptoms,  with
ever,  headache,  shivering,  myalgia  and  poor  general  condi-
ion,  with  no  clinical  or  radiological  signs  of  pneumonia.  The
isease  is  self  limiting,  and  resolves  in  2--7  days.10
Cases  of  extrapulmonary  infection  have  been  docu-
ented,  possibly  due  to  haematogenous  dissemination.
hese  include  prosthetic  valve  endocarditis,  sternotomy
ound  infection,  skin  infections,  abscess,  cellulitis,  sinus-
tis  pericarditis,  myocarditis,  peritonitis,  pancreatitis,  acute
yelonephritis  with  renal  abscess,  and  osteomyelitis,  all  of
hich  are  uncommon.  Elevation  of  alkaline  phosphatase  and
epatic  transaminase  levels  are  a  common  ﬁnding.  Hypona-
raemia  is  more  common  in  L.  pneumophila  infection  than
n  other  forms  of  bacterial  pneumonia.12
iagnosis
iagnosis  is  conﬁrmed  in  the  laboratory  by  culture,  demon-
tration  of  bacterial  antigens  or  DNA  in  body  ﬂuids,  or
vidence  of  a  serologic  response.  Polymorphonuclear  leuco-
ytosis,  azotaemia,  acute  liver  failure,  hyponatraemia,  and
yperphosphataemia  are  all  common  ﬁndings.1,10,12
Legionella  can  be  cultivated  from  sputum,  endotracheal
spirate,  bronchoalveolar  lavage,  open  lung  biopsy  and
leural  ﬂuid.  Sensitivity  of  expectorated  sputum  culture,
owever,  is  low  (50%);  bronchoalveolar  lavage  samples  are
nown  to  have  a  higher  sensitivity.12,13
The  pathogen  grows  after  48  h  incubation  at  37 ◦C  in  aer-
bic  conditions.  Colonies  are  characterized  by  their  blue
olour  and  frosted  glass  appearance.13 On  Gram  staining,
hey  are  shown  as  long,  thin,  Gram-negative  bacilli.  Sam-
les  must  be  incubated  and  regularly  checked  for  at  least
0  days  before  the  culture  is  reported  negative.14
Legionella  can  be  isolated  in  respiratory  tract  and  tis-
ue  specimens  in  2--4  h  using  direct  immunoﬂuorescence.
his  method,  however,  can  give  false  positives  due  to
f
e
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ross-reactivity,  and  the  sensitivity  of  the  test  ranges  from
5%  to  66%.13,14
Immunochromatography,  which  can  detect  antigens  in
rine  in  around  15  min,  is  considered  to  be  a  good  L.  pneu-
ophila  detection  method.  The  test  has  56--97%  sensitivity,
nd  97%  speciﬁcity,  although  it  will  only  detect  L.  pneu-
ophila  serogroup  1.14,15
Serology  using  indirect  immunoﬂuorescence  can  take
etween  3  and  4  weeks  to  detect  antibodies.  A  fourfold
r  higher  rise  in  titre  is  considered  diagnostic.  In  a  single
ample,  a titre  of  1:256  with  documented  pneumonia  is  con-
idered  diagnostic.  These  tests  should  be  interpreted  with
aution  due  to  the  large  number  of  patients  with  asymp-
omatic  infection.2,15,20
Nucleic  acid  ampliﬁcation  tests  for  detecting  Legionella
n  respiratory  tract,  urine,  serum  and  leukocyte  samples
ave  a  sensitivity  of  between  30%  and  86%.13 Table  1  shows
he  different  characteristics  of  the  methods  used  to  diag-
ose  L.  pneumophila  infection.
reatment  and  prognosis
acrolides  or  quinolones  are  the  treatment  of  choice.  In
atients  with  severe  Legionnaire’s  disease,  macrolides  such
s  azithromycin  or  clarithromycin,  or  quinolones  such  as
evoﬂoxacin  or  moxiﬂoxacin  are  recommended.16
Pontiac  fever  is  self-limiting  and  does  not  require  antibi-
tic  therapy.  Erythromycin  was  previously  used,  but  reports
ave  surfaced  of  treatment  failure  in  immunocompromised
atients.16
Quinolones  are  preferred  in  transplant  patients  receiving
yclosporine  or  tacrolimus,  as  macrolides  interfere  with  the
etabolism  of  immunosuppressants.16,17
Duration  of  treatment  can  vary.  In  immunocompetent
atients,  azithromycin  for  5--10  days,  or  a  quinolone  for
0--14  days  is  usually  sufﬁcient.  In  immunocompromised
atients,  therapy  should  be  extended  to  between  14  and
1  days  to  prevent  recurrence.5,16,17
Despite  treatment,  Legionnaire’s  disease  has  a  mortality
ate  of  between  2%  and  5%.  Mortality  among  immunocom-
romised  or  inadequately  treated  patients  is  from  5%  to
0%.1,2,11,17
hlamydophila pneumoniae
orphological  and  structural  characteristics
hlamydophila  pneumoniae  is  an  obligate  intracellular
ram-negative  bacterium  that  can  exist  as  either  an  ele-
entary  or  reticulate  body.  Elementary  bodies,  which  are
iologically  inactive  and  can  survive  in  hostile  environments,
re  the  infective  form  of  the  bacteria.  In  this  form,  the
acterium  enters  the  host  cell,  usually  via  the  respiratory
ract,  where  it  transforms  into  a  reticulate  body.  In  this
etabolically  active,  intracellular,  non-infectious  form,  the
acterium  undergoes  binary  ﬁssion  and  returns  to  its  ele-
entary  body  form.  The  elementary  bodies  are  releasedrom  the  host  cell  after  cell  lysis.23
Sometimes,  due  to  external  factors  such  as  lack  of  nutri-
nts,  reticulate  bodies  remain  in  an  aberrant  form,  which
s  a  relatively  larger  reticulate  body  that  is  still  viable
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Table  1  Characteristics  of  diagnostic  tests  for  L.  pneumophila.
Diagnostic  test  Pros  Cons  Speciﬁcity  (%)  Sensitivity  (%)  Reference
Culture  Sputum,  respiratory
tract  samples,  open
lung  biopsy
specimens  and
pleural  ﬂuid.
Considered  the  gold
standard  for
diagnosis.
Sample  collection
can  be  invasive.
Sensitivity  is  low.
Requires  special
culture  media.
Culture  takes  2--4
days.
100  80--90  Edelstein  &  Meyer,  1994;
Stout  &  Yu  1997;
Harrison  et  al.,  1998;
Maiwald,  Helbig  &  Lück,
1998;  Fields,  Benson,  &
Besser19;  Lück,  Helbig,  &
Schuppler18
Serology  Useful  in  epidemics.  Tests  can  take
between  3  and  4
weeks.  Interpret
with  caution,  due  to
the  high  incidence
of asymptomatic
infection.
95  30--50  Edelstein  &  Meyer,  1994;
Plouffe  et  al.,  1995;
Stout  &  Yu,  1997;
Harrison  et  al.,  1998;
Fields,  Benson,  &
Besser19;  Lück,  Helbig  &
Schuppler18
Immunoﬂuorescence  Test  takes  2--4  h.  Can  give  false
positives  due  to
cross-reactivity.
<60  25--66  Edelstein  &  Meyer,  1994;
Stout  and  Yu,  1997;
Harrison  et  al.,  1998;
Fields,  Benson  &  Besser19
Detects  antigens
in  urine
Fast  results
(15  min).  Results
remain  positive  for
weeks/months.
Only  detects  L.
Pneumophila
serogroup  1.
99--100  75--99  Edelstein  &  Meyer,  1994;
Stout  &  Yu,  1997;
Harrison  et  al.,  1998;
Fields,  Benson  &
Besser19;  Lück,  Helbig,  &
Schuppler18; Uldum  &
Molbak,  2002
PCR Fewer  false
negatives  than
immunoﬂuores-
cence.  Test  is  fast
and  comprehensive
(all  Legionella
species).
Not  commercially
available.
94--99  33--92  Fields,  Benson,  &
Besser19;  Lück,  Helbig,  &
Schuppler18; Uldum  &
Molbak,  2002;  van  der
Zee et  al.21;  Roig  &
Rello22
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cbut  unable  to  infect  other  cells.  In  this  form,  it  is  highly
drug-resistant.  It  has  been  suggested  that  C.  pneumoniae
may  act  as  a  chronic  stimulus  in  the  perpetuation  of  vas-
cular  inﬂammation,  thus  exacerbating  the  atherosclerotic
process.23,24
Epidemiology
In  the  United  States,  C.  pneumoniae  is  estimated  to  cause
over  300,000  cases  of  pneumonia  each  year.  Anti-C. pneu-
moniae  antibodies  are  detected  in  around  half  (50%)  of
individuals  of  20  years  of  age.  The  rate  increases  with  age,
and  antibodies  are  detected  in  70--80%  of  elderly  individuals.
It  is  thought  to  cause  20%  of  all  lower  airway  infections,  and
that  70%  of  these  are  either  asymptomatic  or  not  serious
enough  to  compel  the  patient  to  seek  medical  attention.  It
has  been  suggested  that  between  3%  and  10%  of  all  com-
munity  acquired  pneumonias  are  caused  by  C.  pneumoniae,
and  in  Latin  America  it  is  thought  to  cause  around  6%  of  all
such  diseases.  The  pathogen  is  also  responsible  for  20%  of
all  upper  respiratory  tract  infections.24,25
C
C
nisk  factors
isk  factors  for  C.  pneumoniae  infection  are  thought  to
nvolve  immune  system  functions  and  the  genetic  predispo-
ition  of  the  host.  In  studies  carried  out  in  Asia,  researchers
ave  observed  that  infection  is  extremely  seasonal,  and
eaks  in  the  summer  months.26
Although  many  studies  have  associated  C.  pneumoniae
nfection  with  an  increased  risk  for  heart  disease  due  to  the
nﬂammatory  response  elicited  by  the  pathogen,  the  results
emain  inconclusive.26--30 The  presence  of  this  pathogen  has
lso  been  associated,  albeit  insigniﬁcantly,  with  a  num-
er  of  diseases,  including  asthma  exacerbations,  multiple
clerosis,  chronic  fatigue  syndrome,  Alzheimer’s  disease,
ge-related  macular  degeneration,  chronic  skin  lesions,
erebrovascular  disease.26,27linical  manifestations
.  pneumoniae  causes  sinusitis,  pharyngitis  and  pneumo-
ia,  although  in  most  cases  infection  is  asymptomatic.  The
192  R.  Berebichez-Fridman  et  al.
Table  2  Characteristics  of  diagnostic  tests  for  C.  pneumoniae.
Diagnostic  test  Pros  Cons  Speciﬁcity  (%)  Sensitivity  (%)  Reference
Culture  Gold  standard
method  for
identifying  the
pathogen.
Being  an  obligate
intracellular
pathogen,  specimens
drawn  must  include
host  cells,  and  must
be  preserved  for
between  2  and  6
days.  Special  cell
lines  and  in  vitro
culture  methods  must
be used.
100  50--70  Burillo  &
Bouza31
Microimmunoﬂuorescence
(MIF)  and
immunoﬂuorescence
Serotype-speciﬁc
detection  of  IgM,
IgG  and  IgA  (IgM
greater  than  1:16
or a  four-fold  rise
in IgG  by  MIF).
Cost,  availability,
trained  technicians.
86  79  Burillo  &
Bouza31,
Oba25
PCR  Not  effective  after
start  of  antibiotic
treatment.
Absence  of  a  true
gold  standard
prevents  accurate
evaluation  of  this
93  68  Burillo  &
Bouza31
ﬁ
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rst  manifestation  of  infection  can  resemble  a  typical  viral
nfection,23
C.  pneumoniae  infection  can  present  as:
 Acute  infection:  Although  in  some  immunocompromised
patients  symptoms  can  be  severe  enough  to  merit  hos-
pitalization,  in  most  immunocompetent  patients  clinical
symptoms  are  usually  mild.
 Recurrent  infection:  Recurring  infection  and  its  associated
symptoms  will  depend  on  the  characteristics  of  the  host’s
immunological  system.
 Chronic  infection:  C.  pneumoniae  infection  can  cause
exacerbation  of  COPD  or  asthma.
 C.  pneumoniae  carriers:  Around  2.5%  of  the  population  are
carriers  of  this  pathogen.  They  are  usually  asymptomatic,
although  immune  deﬁciencies  can  cause  acute  symptoms.
Pneumonia  develops  in  2  stages:  at  the  onset,  symp-
oms  are  similar  to  a  cold  (pharyngitis,  laryngitis,  sinusitis),
hich  is  followed  by  moderate  pneumonia.  Pneumonia  last-
ng  between  1  and  4  weeks  is  followed  by  persistent  cough
hat  can  last  several  weeks.24
iagnosis
iagnosis  should  be  based  on  clinical  suspicion.  Certain
adiological  features  are  suggestive  of  C.  pneumoniae
nfection,  such  as  subsegmental,  generally  single  patchy
nﬁltrate,  lobar  or  sublobar  consolidation,  or  interstitial
nﬁltrate  with  hilar  adenopathy.  In  20--25%  of  all  cases,  pleu-
al  effusion,  generally  bilateral,  is  also  seen.28,31
Laboratory  studies  will  usually  ﬁnd  no  changes  in
eukocyte  levels,  inﬂammatory  parameters  can  be  slightly
c
i
w
tlevated,  and  serum  antibodies  may  be  detected.  On  his-
ology,  tissue  samples  of  infected  patients  show  slight
ntra-alveolar  inﬂammation  and  cytoplasmic  inclusion.  It  is
mportant  to  note  that  absence  of  antibodies  does  not  rule
ut  C.  pneumoniae.29 Table  2  shows  the  characteristics  of
ifferent  C.  pneumoniae  diagnostic  procedures.
reatment  and  prognosis
he  treatment  of  choice  is  doxycycline,  although  it  should
ot  be  given  to  children  under  the  age  of  9  years.  Treat-
ent  should  continue  for  10--14  days.  If  symptoms  persist,  a
econd  cycle  should  be  administered.  Second  line  therapies
nclude  erythromycin  (500  mg  4 times  daily),  azithromycin
500  mg  for  between  7  and  10  days),  and  clarithromycin  (1  g
nce  daily  for  10  days).30,31 Antibiotic  therapy  is  usually  suc-
essful,  although  the  cycle  may  need  to  be  repeated  or  the
reatment  prolonged.  Despite  the  large  number  of  studies
ublished  to  date,  the  role  of  this  pathogen  in  other  diseases
as  yet  to  be  investigated  and  clariﬁed.31,32
ycoplasma pneumoniae
orphological  and  structural  characteristics
his  is  the  most  important  species  in  the  Mycoplasmat-
ceae  family  of  bacteria.  M.  pneumoniae  is  an  extracellular,
ree-living  obligate  aerobe  that  only  infects  humans.  In  its
occus  morphology  it  measures  between  0.2  and  0.3  nm;
n  its  bacillus  morphology  it  is  1--2  nm  long  and  0.2  nm
ide.  It  does  not  have  a cell  wall,  which  makes  it  resis-
ant  to  penicillins,  cephalosporins,  vancomycin  and  other
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antibiotics  that  inhibit  cell  wall  synthesis.  M.  pneumoniae
contains  sterols  in  its  cytoplasmic  membrane
It  can  only  be  grown  in  an  artiﬁcial  acellular  medium,  and
takes  6  h  to  replicate.  Its  main  antigenic  determinants  are
glycolipids  and  membrane  proteins.33
Epidemiology
M.  pneumoniae  infection  is  more  common  in  toddlers  in
day  care  centres  and  in  children  aged  5--15  years.  It  causes
between  10%  and  20%  of  all  cases  of  community-acquired
pneumonia,  of  which  60%  occur  in  children.  Extrapulmonary
complications  occur  in  25%  of  all  cases.  It  has  recently
started  to  be  considered  the  main  cause  of  bacterial  pneu-
monia  on  military  bases.  It  colonizes  the  nose,  throat,
and  trachea,  and  is  transmitted  via  respiratory  aerosols.
Respiratory  disease  caused  by  M.  pneumoniae  infection
is  marginally  more  common  in  the  summer  and  autumn
months.34
Each  year,  2  million  new  cases  of  M.  pneumoniae  pneu-
monia  are  reported  in  the  United  States,  with  100,000
hospitalizations.  It  reaches  epidemic  proportions  every  4--8
years.35
M.  pneumoniae  is  the  leading  cause  of  atypical  pneu-
monia  among  children  and  adolescents,  causing  between
10%  and  30%  of  all  cases.  Although  it  is  usually  associated
with  mild  acute  respiratory  infections,  such  as  sore  throat,
pharyngitis,  rhinitis,  and  tracheobronchitis,  it  can  also  cause
more  serious  infections,  such  as  pneumonia  or  lung  abscess.
It  is  associated  with  acute  asthma  exacerbations,  chronic
obstructive  pulmonary  disease,  and  can  even  cause  commu-
nity  outbreaks  on  a  scale  similar  to  ﬂu  epidemics.35,36
Clinical  picture
Infection  is  usually  asymptomatic.  In  the  case  of  recurrent
infection,  or  infection  in  children,  the  following  symptoms
may  present:
It  mainly  presents  as  tracheobronchitis,  followed  2  or
3  weeks  later  by  fever,  general  malaise,  headache  and
unproductive  cough,  which  can  be  accompanied  by  acute
pharyngitis.  Symptoms  can  worsen  and  persist  for  up  to  2
more  weeks,  and  can  even  lead  to  pneumonia.36,37
Uncommon  manifestations  include  myalgia  and  diges-
tive  symptoms.  Secondary  extrapulmonary  complications
can  include  meningoencephalitis,  paralysis,  myelitis,  peri-
carditis,  haemolytic  anaemia,  arthritis,  and  mucocutaneous
lesions.34
Diagnosis
Early,  accurate  diagnosis  of  M.  pneumoniae  infection  is
essential  in  order  to  start  the  right  antibiotic  therapy.  As
it  is  impossible  to  reach  a  diagnosis  based  solely  on  the  non-
speciﬁc  clinical  signs  and  symptoms,  laboratory  tests  must
be  performed.Chest  X-ray  ﬁndings  include  unilateral  or  bilateral  alve-
olar  inﬁltrates,  centrilobular  peribronchovascular  nodules,
areas  of  ground  glass  attenuation,  intrathoracic  lym-
phadenopathy,  and  even  pleural  effusion.
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Various  diagnostic  methods  can  be  used,  including
ulture,  serology  and  molecular  biology  tests.  Due  to  the
low  growth  rate  of  M.  pneumoniae  (colonies  are  only  visible
fter  2--5  weeks),  culture  is  rarely  used.38
The  most  common  diagnostic  method  used  nowadays  is
erology,  mainly  complement  ﬁxation  (CF)  tests.  Sensitiv-
ty,  however,  will  depend  on  whether  the  ﬁrst  sample  was
rawn  in  the  early  or  later  stages  of  development  of  the  dis-
ase,  and  also  on  the  availability  of  paired  serum  samples
rawn  at  an  interval  of  2  or  3  weeks.  Serology  also  include
mmunoglobulin  (IgM)  tests,  which  are  more  sensitive  than
F,  although  IgM  response  may  be  non-speciﬁc  or  even  wholly
bsent,  particularly  in  adults35,37 DNA  hybridization  test-
ng  has  been  suggested  as  a  rapid,  speciﬁc  alternative  to
ulture,  although  it  lack  sensitivity.36
In  view  of  all  these  shortcomings,  a  growing  num-
er  of  clinicians  rely  on  RT-PCR  (reverse  transcription
olymerase  chain  reaction)  for  its  higher  sensitivity  and
peciﬁcity.  RT-PCR  testing  is  performed  on  samples  drawn
rom  nasopharyngeal  and  oropharyngeal  swabs  and  bron-
hoalveolar  lavage,33,35 and  involves  either  isolating  the
acteria  or  detecting  DNA  and  immunoglobulin  sequences
n  mucus  or  blood  samples  draw  from  infected  patients.33
Although  PCR  testing  is  an  effective  M.  pneumoniae
iagnostic  method,  lack  of  standardization  and  commercial
vailability  have  restricted  its  use,  and  no  ofﬁcial  quality
ssurance  guidelines  are  available  to  evaluate  the  effec-
iveness  of  the  methods  used.38 In  addition  to  this,  PCR
quipment  is  often  unavailable  in  some  small  hospitals  and
n  less  afﬂuent  countries  and  regions,  above  all  develop-
ng  countries.  This  is  a  major  challenge  in  Mexico.37 Table  3
hows  the  different  characteristics  of  the  methods  used  to
iagnose  M.  pneumoniae.
reatment  and  prognosis
xperience  has  shown  that  many  M.  pneumoniae  pneu-
onias  are  self-limiting.  However,  medical  treatment  is
eeded  when  symptoms  appear.38 Deﬁnitive  diagnosis  of  M.
neumoniae  is  usually  treated  with  macrolides,  which  can
lso  be  used  in  children.  Nevertheless,  even  when  diag-
osed,  M.  pneumoniae  pneumonias  are  sometimes  confused
ith  Streptococcus  pneumoniae  infection,  as  M.  pneumo-
iae  precedes  and  aggravates  infection  caused  by  other
athogens.38,39
Macrolide  therapy  should  be  given  in  combination
ith  ﬂuoroquinolones,  due  to  the  increase  in  combined
nfection  and  macrolide-resistant  strains.  Among  the  fore-
oing  antibacterials,  the  following  are  recommended:
rythromycin,  tetracyclines,  mainly  doxycycline,  or  ﬂuoro-
uinolones.  All  these  have  been  equally  effective  in  treating
.  pneumoniae, although  doxycycline  and  ﬂuoroquinolones
re  only  used  in  adults.39 Erythromycin  is  occasionally
ssociated  with  adverse  effects,  such  as  gastrointestinal
ymptoms,  abdominal  pain,  nauseas,  vomiting,  diarrhoea,
norexia,  rash,  skin  lesions,  anaphylaxis  and  irreversible
earing  loss.35 Early  treatment  is  important,  as  therapy
tarted  at  a  later  stage  is  far  less  effective.34
Studies  on  the  effectiveness  of  adjuvant  steroid  treat-
ent  in  M.  pneumoniae  infection  have  proved  inconclusive.
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Table  3  Characteristics  of  diagnostic  tests  for  M.  pneumoniae.
Diagnostic  test  Pros  Cons  Speciﬁcity  (%)  Sensitivity  (%)  Reference
Culture  Samples  drawn  from
nasopharyngeal  and
oropharyngeal  swabs
and  bronchoalveolar
lavage.  Accurate
method.
Sample  collection  can
be invasive.  Requires
special  culture
media.  Culture  takes
2--5  weeks.
100  80--90  Xu,  Li,  Chen,  &
Du35
Serology  Most  frequently  used.
Easily  accessible.
Sensitivity  depends
on  whether  the  ﬁrst
sample  was  drawn  in
the early  or  later
stages  of  the  disease,
and  on  the
availability  of  paired
serum  samples  drawn
at  an  interval  of  2  or
3 weeks.
92  30--80 Zhang,  Zong,  Liu,
Hui,  and  Xiao
(2010)
PCR Fast  testing  method.
High  negative
Not  commercially
available.  Not  easily
64--99  69--92  Xu,  Li,  Chen,  &
Du35
D
n
C
A
p
i
p
e
m
o
p
i
a
t
C
T
F
N
R
1
1
1
1
1
1
1predictive  value. accessible.
espite  this,  most  sources  consulted  conclude  that  they  do
ot  contribute  any  major  beneﬁts.39,40
onclusion
typical  pneumonias  are  an  important,  worldwide  health
roblem,  and  all  physicians  should  be  skilled  in  recogniz-
ng,  diagnosing  and  treating  the  main  forms  of  atypical
neumonia.  There  is  scant  reference  in  the  literature  to
pidemiological  studies  on  the  prevalence  of  atypical  pneu-
onias  in  Mexico,  and  what  little  information  is  available  is
ut-dated.  We  believe,  therefore,  that  this  review  should
ave  the  way  for  future  studies  on  this  topic.  It  is  also
mportant  to  analyse  the  short-  and  long-term  impact  of
typical  pneumonias  in  Mexico,  and  the  systemic  implica-
ions  of  infection  by  each  pathogen.
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